
Shattuck Labs (STTK) Stock Forecast & Price Target
Shattuck Labs (STTK) Analyst Ratings
Bulls say
Shattuck Labs is viewed favorably because its selective DR3-targeting platform could address a clear class-wide weakness in anti-TL1A programs—immunogenicity—while preserving strong efficacy potential in inflammatory bowel disease and hidradenitis suppurativa. The lead asset SL-325 showed a 3.7% ADA rate in Phase 1, durable DR3 blockade, full occupancy at low dose, and dose-proportional PK supporting quarterly dosing, while the Phase 2b Crohn’s study was expanded to ~232 patients with topline data expected in 1H28. Financially, existing cash is expected to fund operations into 2029, and risk-adjusted modeling assigns meaningful value to SL-325 across Crohn’s, UC, and HS, with added upside from SL-846.
Bears say
Shattuck Labs is a high-risk biotechnology story whose value depends heavily on SL-325 and a small pipeline of early-stage DR3 assets, leaving it exposed to clinical failure, safety signals, immunogenicity, and regulatory delays that could derail development or slow uptake. Competition around inflammatory targets is intensifying, and the company also faces legal uncertainty around patent protection plus manufacturing and commercial execution risks that could weaken its position even if data remain encouraging. Financially, it does not anticipate profitability for several years and expects to require additional funding to advance trials, with only a 20% PoS for IBD and a valuation model that is highly sensitive to assumptions and timeline shifts.
This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.
Shattuck Labs (STTK) Analyst Forecast & Price Prediction
Start investing in Shattuck Labs (STTK)
Order type
Buy in
Order amount
Est. shares
0 shares